Previous studies have demonstrated the superiority of potent P2Y12 inhibitors over clopidogrel in DAPT among patients with acute coronary syndrome [18, 19], and in strategies involving early transition to monotherapy after PCI [6, 20]. This evidence concerns the gene P2RY12 and acute coronary syndrome.